The three major US stock indexes were mixed around midday Monday, the first trading day after the release of better-than-expected employment numbers that meant lower chances of future rate cuts.
In corporate news, Moderna (MRNA) shares fell over 20% in recent trading after the company said it now expects 2025 revenue to be between $1.5 billion and $2.5 billion, down from the previous range of $2.5 billion to $3.5 billion.
Cleveland-Cliffs (CLF) is teaming up with Nucor (NUE) in a potential bid for US Steel (X), CNBC reported, citing unnamed sources. Shares of Cleveland-Cliffs rose 4.7%, Nucor advanced 3.6% and US Steel gained 8.4%.
Johnson & Johnson (JNJ) agreed to acquire Intra-Cellular Therapies (ITCI) for about $14.6 billion in cash. The $132-per-share deal will likely close later this year. Shares of Intra-Cellular Therapies were up 34%, while Johnson & Johnson was up 0.4%.
Howard Hughes Holdings' (HHH) shareholders have been sent a letter by Pershing Square offering to acquire a controlling stake in Howard Hughes by a newly created subsidiary. Pershing is seeking to acquire approximately 11.7 million shares of Howard Hughes' stock at $85 each. Howard Hughes shares climbed 7.7%.
Apple's (AAPL) new fees for app developers are under scrutiny from EU competition watchdogs amid concerns they may increase costs for software makers, Bloomberg reported, quoting unnamed sources. Apple shares were down 2.3%.
Price: 33.60, Change: -8.65, Percent Change: -20.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.